AU2002334051B2 - Aminoglycoside lipid derivatives for transfection - Google Patents
Aminoglycoside lipid derivatives for transfection Download PDFInfo
- Publication number
- AU2002334051B2 AU2002334051B2 AU2002334051A AU2002334051A AU2002334051B2 AU 2002334051 B2 AU2002334051 B2 AU 2002334051B2 AU 2002334051 A AU2002334051 A AU 2002334051A AU 2002334051 A AU2002334051 A AU 2002334051A AU 2002334051 B2 AU2002334051 B2 AU 2002334051B2
- Authority
- AU
- Australia
- Prior art keywords
- transfecting
- cells
- chosen
- composition according
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000001890 transfection Methods 0.000 title claims abstract description 61
- 229940126575 aminoglycoside Drugs 0.000 title claims abstract description 43
- 150000002632 lipids Chemical class 0.000 title claims description 49
- 150000001875 compounds Chemical class 0.000 claims abstract description 95
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 67
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 67
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 67
- 125000006850 spacer group Chemical group 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 79
- 239000000203 mixture Substances 0.000 claims description 74
- 108020004414 DNA Proteins 0.000 claims description 70
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 claims description 53
- 102000004169 proteins and genes Human genes 0.000 claims description 49
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 35
- -1 isepamycin Chemical compound 0.000 claims description 30
- 229920001223 polyethylene glycol Polymers 0.000 claims description 22
- 235000012000 cholesterol Nutrition 0.000 claims description 20
- 239000002671 adjuvant Substances 0.000 claims description 19
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 16
- 230000008685 targeting Effects 0.000 claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- 229960000318 kanamycin Drugs 0.000 claims description 15
- 229930182823 kanamycin A Natural products 0.000 claims description 15
- 230000001225 therapeutic effect Effects 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 12
- 230000006870 function Effects 0.000 claims description 12
- 230000007935 neutral effect Effects 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 229930193140 Neomycin Natural products 0.000 claims description 10
- 229960004927 neomycin Drugs 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 238000012546 transfer Methods 0.000 claims description 10
- 125000001931 aliphatic group Chemical group 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 6
- 230000003637 steroidlike Effects 0.000 claims description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 5
- 229930027917 kanamycin Natural products 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229960001914 paromomycin Drugs 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- JNUKAMAZVDNYCT-ZFYYWSQPSA-N (3S,8S,9S,10R,13S,14S,17S)-3-hydroxy-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-16-carboxamide Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(C(N)=O)[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 JNUKAMAZVDNYCT-ZFYYWSQPSA-N 0.000 claims description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 4
- 102000053602 DNA Human genes 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 4
- 150000001409 amidines Chemical class 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 230000000692 anti-sense effect Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 229940126601 medicinal product Drugs 0.000 claims description 3
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 150000008163 sugars Chemical class 0.000 claims description 3
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 claims description 2
- GRRNUXAQVGOGFE-SVNOMHMPSA-N (3'r,3as,4s,4's,5'r,6r,6'r,7s,7as)-4-[(1s,2r,3s,5r,6s)-3-amino-2,6-dihydroxy-5-(methylamino)cyclohexyl]oxy-6'-[(1s)-1-amino-2-hydroxyethyl]-6-(hydroxymethyl)spiro[4,6,7,7a-tetrahydro-3ah-[1,3]dioxolo[4,5-c]pyran-2,2'-oxane]-3',4',5',7-tetrol Chemical compound O[C@H]1[C@H](NC)C[C@H](N)[C@@H](O)[C@@H]1O[C@H]1[C@H]2OC3([C@@H]([C@@H](O)[C@@H](O)[C@@H]([C@@H](N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-SVNOMHMPSA-N 0.000 claims description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 2
- YGPZWPHDULZYFR-DPAQBDIFSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-amine Chemical compound C1C=C2C[C@@H](N)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 YGPZWPHDULZYFR-DPAQBDIFSA-N 0.000 claims description 2
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 claims description 2
- XIIAYQZJNBULGD-UHFFFAOYSA-N (5alpha)-cholestane Natural products C1CC2CCCCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 XIIAYQZJNBULGD-UHFFFAOYSA-N 0.000 claims description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims description 2
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 claims description 2
- ZXWQZGROTQMXME-WXUJBLQXSA-N 2-hydroxy-n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]tetracosanamide Chemical class CCCCCCCCCCCCCCCCCCCCCCC(O)C(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O ZXWQZGROTQMXME-WXUJBLQXSA-N 0.000 claims description 2
- 239000004380 Cholic acid Substances 0.000 claims description 2
- ASXBYYWOLISCLQ-UHFFFAOYSA-N Dihydrostreptomycin Natural products O1C(CO)C(O)C(O)C(NC)C1OC1C(CO)(O)C(C)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O ASXBYYWOLISCLQ-UHFFFAOYSA-N 0.000 claims description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 claims description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 claims description 2
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 claims description 2
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 claims description 2
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 claims description 2
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 claims description 2
- 229960004821 amikacin Drugs 0.000 claims description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 2
- 229960005397 arbekacin Drugs 0.000 claims description 2
- MKKYBZZTJQGVCD-XTCKQBCOSA-N arbekacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)CC[C@H]1N MKKYBZZTJQGVCD-XTCKQBCOSA-N 0.000 claims description 2
- 229930183167 cerebroside Natural products 0.000 claims description 2
- 150000001784 cerebrosides Chemical class 0.000 claims description 2
- XIIAYQZJNBULGD-LDHZKLTISA-N cholestane Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 XIIAYQZJNBULGD-LDHZKLTISA-N 0.000 claims description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 2
- 235000019416 cholic acid Nutrition 0.000 claims description 2
- 229960002471 cholic acid Drugs 0.000 claims description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 2
- 150000001982 diacylglycerols Chemical class 0.000 claims description 2
- 229960003807 dibekacin Drugs 0.000 claims description 2
- JJCQSGDBDPYCEO-XVZSLQNASA-N dibekacin Chemical compound O1[C@H](CN)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N JJCQSGDBDPYCEO-XVZSLQNASA-N 0.000 claims description 2
- ASXBYYWOLISCLQ-HZYVHMACSA-N dihydrostreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O ASXBYYWOLISCLQ-HZYVHMACSA-N 0.000 claims description 2
- 229960002222 dihydrostreptomycin Drugs 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 239000007972 injectable composition Substances 0.000 claims description 2
- 210000004400 mucous membrane Anatomy 0.000 claims description 2
- 230000004962 physiological condition Effects 0.000 claims description 2
- 229960003485 ribostamycin Drugs 0.000 claims description 2
- 229930190553 ribostamycin Natural products 0.000 claims description 2
- NSKGQURZWSPSBC-NLZFXWNVSA-N ribostamycin Chemical compound N[C@H]1[C@H](O)[C@@H](O)[C@H](CN)O[C@@H]1O[C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](CO)O2)O)[C@H](O)[C@@H](N)C[C@H]1N NSKGQURZWSPSBC-NLZFXWNVSA-N 0.000 claims description 2
- NSKGQURZWSPSBC-UHFFFAOYSA-N ribostamycin A Natural products NC1C(O)C(O)C(CN)OC1OC1C(OC2C(C(O)C(CO)O2)O)C(O)C(N)CC1N NSKGQURZWSPSBC-UHFFFAOYSA-N 0.000 claims description 2
- 229920002477 rna polymer Polymers 0.000 claims description 2
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 claims description 2
- 150000003408 sphingolipids Chemical class 0.000 claims description 2
- 229960005322 streptomycin Drugs 0.000 claims description 2
- 229960000707 tobramycin Drugs 0.000 claims description 2
- GNVMUORYQLCPJZ-UHFFFAOYSA-N carbamothioic s-acid Chemical group NC(S)=O GNVMUORYQLCPJZ-UHFFFAOYSA-N 0.000 claims 2
- 238000000338 in vitro Methods 0.000 abstract description 23
- 238000001727 in vivo Methods 0.000 abstract description 18
- 125000003473 lipid group Chemical group 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 91
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000013612 plasmid Substances 0.000 description 30
- 230000014509 gene expression Effects 0.000 description 29
- 239000002502 liposome Substances 0.000 description 27
- 230000001413 cellular effect Effects 0.000 description 23
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 22
- 108060001084 Luciferase Proteins 0.000 description 21
- 239000005089 Luciferase Substances 0.000 description 21
- 238000009472 formulation Methods 0.000 description 21
- 239000000047 product Substances 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
- 125000002091 cationic group Chemical group 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 17
- 150000001412 amines Chemical class 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 239000013592 cell lysate Substances 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 108700008625 Reporter Genes Proteins 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 5
- 101150055766 cat gene Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- JTQQDDNCCLCMER-CLFAGFIQSA-N (z)-n-[(z)-octadec-9-enyl]octadec-9-en-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCNCCCCCCCC\C=C/CCCCCCCC JTQQDDNCCLCMER-CLFAGFIQSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical group NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 210000003437 trachea Anatomy 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 230000006181 N-acylation Effects 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- QNEPTKZEXBPDLF-JDTILAPWSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] carbonochloridate Chemical compound C1C=C2C[C@@H](OC(Cl)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QNEPTKZEXBPDLF-JDTILAPWSA-N 0.000 description 2
- 108020002494 acetyltransferase Proteins 0.000 description 2
- 102000005421 acetyltransferase Human genes 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- CSOJECDGWHHWRS-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylcarbamothioyl]carbamate Chemical compound CC(C)(C)OC(=O)NC(=S)NC(=O)OC(C)(C)C CSOJECDGWHHWRS-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 150000003558 thiocarbamic acid derivatives Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- ZAQWGGKIMQIVGM-UHFFFAOYSA-N (4-nitrophenyl) 2-trimethylsilylethyl carbonate Chemical compound C[Si](C)(C)CCOC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ZAQWGGKIMQIVGM-UHFFFAOYSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 1
- JAPYIBBSTJFDAK-UHFFFAOYSA-N 2,4,6-tri(propan-2-yl)benzenesulfonyl chloride Chemical compound CC(C)C1=CC(C(C)C)=C(S(Cl)(=O)=O)C(C(C)C)=C1 JAPYIBBSTJFDAK-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 108010002913 Asialoglycoproteins Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 1
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000715496 Escherichia coli Chloramphenicol acetyltransferase Proteins 0.000 description 1
- 101000793935 Escherichia coli Chloramphenicol acetyltransferase Proteins 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 102000037909 Folate transporters Human genes 0.000 description 1
- 108091006783 Folate transporters Proteins 0.000 description 1
- 229930183217 Genin Natural products 0.000 description 1
- 102000004038 Glia Maturation Factor Human genes 0.000 description 1
- 108090000495 Glia Maturation Factor Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229940124084 Interleukin 1 antagonist Drugs 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- LGDSHSYDSCRFAB-UHFFFAOYSA-N Methyl isothiocyanate Chemical compound CN=C=S LGDSHSYDSCRFAB-UHFFFAOYSA-N 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102100021010 Nucleolin Human genes 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 102100032889 Sortilin Human genes 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- PLZVEHJLHYMBBY-UHFFFAOYSA-N Tetradecylamine Chemical compound CCCCCCCCCCCCCCN PLZVEHJLHYMBBY-UHFFFAOYSA-N 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- NIGUVXFURDGQKZ-UQTBNESHSA-N alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O NIGUVXFURDGQKZ-UQTBNESHSA-N 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 125000000909 amidinium group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003914 blood derivative Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical group NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 108010064060 high density lipoprotein receptors Proteins 0.000 description 1
- 102000054823 high-density lipoprotein particle receptor activity proteins Human genes 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960002523 mercuric chloride Drugs 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- APBBAQCENVXUHL-UHFFFAOYSA-N n,n-diethylethanamine;2,2,2-trifluoroacetic acid Chemical compound CCN(CC)CC.OC(=O)C(F)(F)F APBBAQCENVXUHL-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- SSVLHTOYYHGIND-UHFFFAOYSA-N n-benzyloxycarbonyloxy-5-norbornene-2,3-dicarboximide Chemical compound O=C1C2C(C=C3)CC3C2C(=O)N1OC(=O)OCC1=CC=CC=C1 SSVLHTOYYHGIND-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 108010044762 nucleolin Proteins 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 102000005162 pleiotrophin Human genes 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000003956 transport vesicle Anatomy 0.000 description 1
- 150000008648 triflates Chemical class 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
The invention concerns novel transfecting compounds consisting of an aminoglycoside bound to a lipid via a spacer, and their polyguanidyl derivatives. Said compounds are useful for in vitro, ex vivo or in vivo transfection of nucleic acids in different cell types.
Description
WO 03/018603 PCT/FR02/02959 LIPID DERIVATIVES OF AMINOGLYCOSIDES The present invention relates to novel compounds which allow the transfer of nucleic acids into cells. More precisely, these novel compounds are lipid derivatives of aminoglycosides and their polyguanidylated derivatives. They are useful for the in vitro, ex vivo or in vivo transfection of nucleic acids into various cell types.
With the development of biotechnology it has become necessary to efficiently transfer nucleic acids into cells. This may involve transferring nucleic acids into cells in vitro, for example for producing recombinant proteins, or in the laboratory, for studying the regulation of gene expression, cloning genes or any other manipulation involving DNA. It may also involve transferring nucleic acids into cells in vivo, for example for the creation of transgenic animals, the production of vaccines, labeling studies or also therapeutic approaches. It may also involve transferring nucleic acids into cells ex vivo, in approaches for bone marrow transplantation or for immunotherapy, or other methods involving the transfer of genes into cells removed from an organism, with a view to subsequently readministering them.
Today, several methods are proposed for the intracellular delivery of exogenous genetic material.
One of them, in particular, is based on the use of nonviral vectors, which constitutes a very advantageous alternative compared to viral methods, which are not entirely free of risks. These synthetic vectors have two main functions: to complex and compact the nucleic acid to be transfected, and to promote its passage across the plasma membrane and, optionally, across the nuclear envelope.
Several families of synthetic vectors have thus been developed, such as for example polymers or biochemical vectors (consisting of a cationic protein associated with a cellular receptor), but considerable progress has especially been accomplished with the development of lipofectants, and more particularly cationic lipids. It has thus been demonstrated that cationic lipids, due to their overall positive charge, interfere spontaneously with DNA, which is negative overall, forming nucleolipid complexes capable of both protecting the DNA against nucleases and attaching to cell membranes for intracellular release of the DNA.
Thus, most of the nonviral vectors developed to date are based on amine protonation to allow binding to the
DNA.
Various types of cationic lipid have been synthesized to date: lipids comprising a quaternary ammonium group (for example DOTMA, DOTAP, DMRIE, DLRIE, etc.), lipopolyamines, such as for example DOGS, DCchol or the lipopolyamines disclosed in patent application WO 97/18185, lipids which combine both a quaternary ammonium group and a polyamine, such as DOSPA, or lipids comprising various other cationic entities derived from amines, in particular amidinium groups (for example ADPDE, ADODE or the lipids of patent EP 0 888 379 B1 or US 6,143,729, in particular
BGTC).
Although the structure/activity relationships of cationic lipids are not yet really understood, it is generally considered that the nature of the cationic component has a major impact on the transfection activity, although it is the nature and the physicochemical properties of the whole molecule (such as the hydrophobicity/hydrophilicity balance, the interactions with colipids, etc.) which determine the efficiency of a given cationic lipid in fine (see, for example, Felgner et al., Am. Chem. Soc., 1996, pp. 177- 190).
For this reason, in the past few years, a great deal of effort has been spent in developing cationic lipids which have novel cationic entities. The object of the present invention is precisely to provide novel transfecting compounds which are original by virtue of their cationic component consisting of aminoglycosides or of their polyguanidylated derivatives, and which can be used effectively for the in vitro, ex vivo or in vivo transfection of nucleic acids. These novel compounds are particularly advantageous because the aminoglycosides can interact with three-dimensional substructures found in a large variety of RNA molecules (Walter et al., Curr. Opin.
Chem. Biol., 1999, 3, pp. 694-704) and they therefore constitute novel cationic groups which have structural characteristics particularly suitable for synthesizing a large variety of transfecting compounds.
Specifically, aminoglycosides are multifunctional compounds containing up to 6 amino groups and several hydroxyl functions. Selective acylation of one or more of these groups has therefore made it possible to obtain aminoglycosides which have the lipophilic properties required for use in transfection. In addition, aminoglycosides can be easily polyguanidylated in a single step, which makes it possible, for example, to synthesize transfecting compounds having guanidinium groups in place of amines, in their cationic component. Finally, these novel transfecting compounds are also particularly advantageous from a pharmaceutical point of view since the aminoglycosides which constitute their cationic component are natural compounds which are already widely used in pharmacy as antibiotics, their 00
O
C antibacterial activity in fact being derived from their interaction with prokaryotic rRNAs (Moazed et al., Nature, 1987, 327, pp. 389-394; Puhrohit et al., Nature, 1994, 370, pp. 659-662).
SThe subject of the present invention is transfecting compounds of the general formula -i A-Y-L
(I)
Cin which: 0 10 A represents an aminoglycoside or its polyguanidylated derivative, Y represents a spacer, and L represents: either a radical -(R 1
)R
2 with R 1 and R 2 which represent, independently of one another, a hydrogen atom or a fatty aliphatic chain or R 1 or R 2 is absent, it being understood that at least one of R 1 and R 2 represents a fatty aliphatic chain chosen from alkyl radicals containing 14, 16, 18, 20 or 22 carbon atoms and optionally 1, 2 or 3 unsaturations, or a radical -N-R 3 or -O-R 3 with R 3 which represents a steroidal derivative where appropriate in the form of an isomer, of a mixture or of a salt.
For the purpose of the present invention, the term "aminoglycoside" (or "aminosides") is intended to mean natural heterosides formed by the combining of a genin of the aminocyclitol group with generally several saccharides, at least one of which is an aminosugar (osamine). They may therefore be considered to be pseudooligosaccharides having antibiotic properties. By way of example of suitable aminoglycosides, mention may be made of amikacin, arbekacin, deoxyhydrostreptomycin, destomycin A, dibekacin, dihydrostreptomycin, genticin, gentamycin, hygromycin, isepamycin, kanamycin, micronomycin, paromomycin, ribostamycin, streptomycin, streptonicozide, neomycin, tobramycin, sisomycin or semi-synthetic aminosides.
The polyguanidylated derivative of an aminoglycoside according to the invention is the aminoglycoside for which the amino functions have been replaced with guanidinium functions. For example, the polyguanidylated derivative of kanamycin, or guanidinokanamycin, has been described by Baker et al.
Org. Chem., 2000, 65, pp. 9054-9058).
According to the present invention, the term "spacer" is intended to mean any chemical group which makes it possible both to form the bond between the aminoglycoside or its polyguanidylated derivative and the lipid component of the molecule, and to distance these two components in order to reduce any undesired interaction between them. Consequently, the spacer is a difunctional chemical group which may, for example, consist of one or more chemical functions chosen from alkyls having 1 to 6 carbon atoms, ketone, ester, ether, amino, amide, amidine, carbamate or thiocarbamate functions, glycerol, urea, thiourea or aromatic rings. For example, the spacer may be chosen from the radicals of formula: -NH-C -CH 2
-CH
2
-W-(CH
2 or: (CH2) jin which i, j and k are integers chosen between 1 and 6 inclusive, and W and W' are groups, which may be identical or different, chosen from ketone, ester, ether, amino, amide, amidine, carbamate or thiocarbamate functions, glycerol, urea, thiourea or aromatic rings.
For the purpose of the present invention, the term "fatty aliphatic chains" is intended to mean saturated or unsaturated alkyl radicals containing to 22 carbon atoms and optionally containing one or more hetero atoms, provided that said fatty aliphatic chains have lipid properties. Preferably, they are linear or branched alkyl radicals containing 10 to 22 carbon atoms and 1, 2 or 3 unsaturations. Preferably, said alkyl radicals comprise 10, 12, 14, 16, 18, 20 or 22 carbon atoms. Mention may be made more particularly of the aliphatic radicals -(CH 2 11
CH
3
-(CH
2 )1 3
CH
3
(CH
2 15
CH
3 and -(CH 2 1 7
CH
3 For the purpose of the present invention, the term "steroidal derivatives" is intended to mean polycyclic compounds of the cholestane type. These compounds may or may not be natural and are preferably chosen from cholesterol, cholestanol, 3-a-5-cyclo-5-acholestan-6-p-ol, cholic acid, cholesteryl formiate, cholestanyl formiate, 3-a-5-cyclo-5-a-cholestan-6-p-yl formiate, cholesterylamine, 6-(1,5-dimethylhexyl)- [2,3]cyclopenta[l,2-f]naphthalen-10-ylamine or cholestanylamine.
The transfecting compounds, for which A and Y are as defined above in general formula and L is a radical -OR 3 with R 3 which represents a steroidal derivative, constitute a subclass of transfecting compounds which are preferred for the purpose of the present invention.
Even more preferably, the transfecting compounds according to the present invention are chosen from the compounds of general formula for which A and Y are as defined above and L is a radical -OR 3 with
R
3 which represents a cholesterol radical.
Transfecting compounds which are even more particularly preferred are in particular 3p[6'kanamycin-carbamoyl]cholesterol ("KanaChol") of formula: KanaChol 33[6'-(1,3,3"-triguanidino)kanamycin-carbamoyl]cholesterol ("TGKC") of formula:
OH
HO HO OH 3-3 OHO +N 0O 0" ,O NH
H
+NH3+ N H NKn HN+ TGKC and (5"-aminoethylsulfanyl) neomycin carbamoylcholesterol ("Neochol") of formula: carbamoylcholesterol ("Neochol") of formula: 0N O NH3 H OH 0 OH ,NH +H3N -1 OH
HO
NeoChol It is understood that the present invention also relates to the isomers of the products of general formula when they exist, and also the mixtures thereof, or the salts thereof.
In particular, the compounds of the invention may be in the form of nontoxic and pharmaceutically acceptable salts. These nontoxic salts comprise salts with inorganic acids (for example hydrochloric, sulfuric, hydrobromic, phosphoric, nitric acid) or with organic acids (acetic, propionic, succinic, maleic, hydroxymaleic, benzoic, fumaric, methanesulfonic, trifluoroacetic or oxalic acid).
The compounds of general formula (I) according to the present invention are prepared by carrying out the following steps, in the order presented or according to any other known and equally suitable variant, using techniques of conventional organic synthesis, in solution or on solid supports, which are well known to those skilled in the art: 1) Production of the lipid component L When the lipid component L of the compounds of general formula is represented by a radical
(RI)R
2 attached, for example, to a nitrogen atom of the spacer, the amine of formula HN(RI)R 2 is first of all formed. Said amine may be obtained by condensation of a carboxylic acid and an amine, one containing the substituent R 1 and the other the substituent R 2 so as to form the corresponding amide, followed by reduction of said amide thus obtained.
The formation of the amide is advantageously carried out by mixing the constituents and melting by heating to a temperature greater than the melting temperature of the substances involved, in general between 20 0 C and 200 0 C, and then eliminating the water produced by dehydration of the medium; or more advantageously in the presence of a desiccating agent, such as, for example, phosphorus pentoxide or any other substance which can absorb water. This intermediate amide may also be formed using a variant of this method or any other method of amide formation (such as, for example, coupling of the peptide type) involving carboxylic acids or their derivatives, conditions and reagents which are varied Larock, Comprehensive Organic Transformations, VCH editors] and well known to those skilled in the art.
Reduction of the amide obtained above to an amine of formula HN(R 1
)R
2 may be carried out, for example, using a reducing agent such as lithium aluminum hydride, or any other hydride or reducing agent which is effective in this case. The procedure is then preferably carried out in a nonprotic solvent (for example tetrahydrofuran or ethers), at a temperature lower than the boiling temperature of the solvent and under a dry and/or inert atmosphere.
According to another variant, the lipid component denoted as NH(R 1
)R
2 may be commercially available.
When the lipid component L of the compounds of general formula is represented by a radical -NR 3 or -OR 3 it is preferably chosen from commercially available products.
2) Grafting of the spacer Y The spacer Y is then attached to the lipid component L obtained in the preceding step, according to conventional techniques known to those skilled in the art. According to a preferred variant, an amide bond is formed by N-acylation of the lipid component L in a suitable solvent, such as dichloromethane, chloroform, tetrahydrofuran or any other ether, at a temperature lower than the boiling temperature of the solvent, and under a dry and/or inert atmosphere. This reaction preferably takes place in the presence of an amine base, such as N, N-dimethylaminopyridine, or in the presence of this base mixed with nonnucleophilic amine bases, such as triethylamine or ethyldiisopropylamine. Pyridine may also be used, alone or mixed with another base, diluted with one of the solvents mentioned or used, itself, as a solvent.
According to another variant, when the lipid component L represents a radical -OR 3 treatment, with phosgene, of the corresponding alcohol R 3 0H gives a chloroformiate (sometimes commercially available).
3) Grafting of the aminoglycoside The grafting of the aminoglycoside onto the Y-L combination is carried out using the amine and/or hydroxyl functions carried by the aminoglycoside, whether they are present in the natural compound or originate from a modification produced according to the conventional methods known to those skilled in the art.
According to a variant, an amide bond is formed by N-acylation of an amine function of the aminoglycoside with the Y-L combination suitably activated according to the conventional methods used to create a peptide bond.
When the lipid component L of the compounds of general formula is represented by the radical
-OR
3 a preferred possibility consists in linking the components A and L via a carbamate bond obtained by treating the aminoglycoside with the chloroformiate, sometimes commercially available, of the alcohol This reaction takes place in a suitable solvent, such as dichloromethane, chloroform, tetrahydrofuran, dimethylformamide or any other ether, at a temperature lower than the boiling temperature of the solvent, under a dry and/or inert atmosphere and in the presence of a nonnucleophilic amine base, such as triethylamine, ethyldiisopropylamine or pyridine.
In general, the aminoglycosides preferentially used in the context of the invention are all commercially available.
4) Transformation of the amines into guanidines The transformation of the amine functions of the aminoglycoside into guanidine functions may be easily carried out according to the techniques known to those skilled in the art, in particular the techniques described, for example, by Baker et al. Org. Chem., 2000, 65, pp. 9054-8), Luedtke et al. Am. Chem., 2000, 122, pp. 12035-12036) or Iwanowicz et al. (Synth.
Commun. 1993, 23, pp. 1443-1445). Advantageously, the technique and the reagents described by Iwanowicz et al. (Synth. Commun. 1993, 23, pp. 1443-1445) are used.
Naturally, when the various substituents may interfere with the reaction, it is preferable to protect them beforehand with radicals which are compatible and which can be introduced and eliminated without affecting the rest of the molecule. This is carried out according to the conventional methods known to those skilled in the art, and in particular according to the methods described in T. W. Greene, Protective Groups in Organic Synthesis, Wiley- Interscience, in McOmie, Protective Groups in Organic Chemistry, Plenum Press, or in P. J. Kocienski, Protecting Groups, Thieme.
Moreover, each step of the preparation process may be followed, where appropriate, by steps for separating and purifying the compound obtained, according to any method known to those skilled in the art.
Another subject of the invention relates to the compositions comprising a transfecting compound according to the invention and a nucleic acid. The respective amounts of each component may be easily adjusted by those skilled in the art depending on the transfecting compound used, on the nucleic acid and on the desired applications (in particular on the type of cell to be transfected).
For the purpose of the invention, the term "nucleic acid" is intended to mean both a deoxyribonucleic acid and a ribonucleic acid. They may be natural or artificial sequences, and in particular genomic DNA (gDNA), complementary DNA (cDNA), messenger RNA (mRNA), transfer RNA (tRNA) or ribosomal RNA (rRNA), hybrid sequences such as DNA/RNA chimeroplasts, or synthetic or semi-synthetic sequences, modified oligonucleotides or unmodified oligonucleotides. These nucleic acids may be of human, animal, plant, bacterial, viral, etc. origin. They may be obtained using any technique known to those skilled in the art, in particular by screening libraries, by chemical synthesis or by mixed methods including the chemical or enzymatic modification of sequences obtained by screening libraries. They may be modified chemically.
In general, they contain at least 10, 20, 50 or 100 consecutive nucleotides, and preferably at least 200 consecutive nucleotides. Even more preferably, they contain at least 500 consecutive nucleotides.
With regard more particularly to the deoxyribonucleic acids, they may be single-stranded or double-stranded, as well as short oligonucleotides or longer sequences. In particular, the nucleic acids advantageously consist of plasmids, vectors, episomes, expression cassettes, etc. These deoxyribonucleic acids may carry a prokaryotic or eukaryotic origin of replication which may or may not be functional in the target cell, one or more marker genes, sequences which regulate transcription or replication, genes of therapeutic interest, antisense sequences which may or may not be modified, regions for binding to other cellular components, etc.
Preferably, the nucleic acid comprises one or more genes of therapeutic interest under the control of regulatory sequences, for example one or more promoters and a transcriptional terminator which are active in the target cells.
For the purpose of the invention, the expression "gene of therapeutic interest" is intended in particular to mean any gene encoding a protein product which has a therapeutic effect. The protein product thus encoded may in particular be a protein or a peptide. This protein product may be exogenous, homologous or endogenous with respect to the target cell, i.e. a product which is normally expressed in the target cell when the latter does not show any pathological condition. In this case, the expression of a protein makes it possible, for example, to compensate for insufficient expression in the cell or the expression of a protein which is inactive or weakly active due to a modification, or to overexpress the said protein. The gene of therapeutic interest may also encode a mutant of a cellular protein, which has increased stability, modified activity, etc. The protein product may also be heterologous with respect to the target cell. In this case, an expressed protein may, for example, add to or introduce deficient activity in the cell, making it possible for it to combat a pathological condition, or stimulate an immune response.
Among the therapeutic products for the purpose of the present invention, mention may be made more particularly of enzymes, blood derivatives, hormones, lymphokines and cytokines and inhibitors thereof or antagonists thereof (interleukins, interferons, TNF, interleukin 1 antagonists, soluble receptors for interleukin 1 and TNFa, etc.: FR 92/03120), growth factors, neurotransmitters or their precursors or synthetic enzymes, trophic factors (BDNF, CNTF, NGF, IGF, GMF, aFGF, bFGF, NT3, HARP/pleitrophin, etc.) apolipoproteins (ApoAI, ApoAIV, ApoE, etc.: FR 93/05125), dystrophin or a minidystrophin (FR 91/11947), the CFTR protein associated with cystic fibrosis, tumor suppressor genes (p53, Rb, RaplA, DCC, k-rev, etc.: FR 93/04745), genes encoding factors involved in clotting (factors VII, VIII and IX), genes involved in DNA repair, suicide genes (thymidine kinase, cytosine deaminase), genes for hemoglobin or for other protein transporters, metabolic enzymes, catabolic enzymes, etc.
The nucleic acid of therapeutic interest may also be an antisense sequence or gene or a DNA encoding an RNA with a ribozyme function, the expression of which in the target cell makes it possible to control the expression of genes or the transcription of cellular mRNAs. Such sequences may, for example, be transcribed, in the target cell, into RNAs complementary to cellular mRNAs and thus block their translation into protein, according to the technique described in patent EP 140 308. The therapeutic genes also comprise the sequences encoding ribozymes, which are capable of selectively destroying target RNAs (EP 321 201) As indicated above, the nucleic acid may also comprise one or more genes encoding an antigenic peptide capable of generating, in humans or animals, an immune response. In this particular embodiment, the invention allows the production of vaccines or the carrying out of immunotherapeutic treatments, applied to humans or to animals, in particular for treating or preventing infections, for example viral or bacterial infections, or cancers. They may in particular be antigenic peptides specific for the Epstein-Barr virus, for the HIV virus, for the hepatitis B virus (EP 185 573), for the pseudorabies virus, for the syncitia forming virus or for other viruses, or antigenic peptides specific for tumors (EP 259 212).
Preferentially, the nucleic acid also comprises sequences which allow the expression of the gene of therapeutic interest and/or of the gene encoding the antigenic peptide, in the desired cell or organ. They may be sequences which are naturally responsible for the expression of the gene in question when these sequences are capable of functioning in the infected cell. They may also be sequences of different origin (responsible for the expression of other proteins or even synthetic). In particular, they may be promoter sequences of eukaryotic or viral genes. For example, they may be promoter sequences derived from the genome of the cell intended to be infected.
Similarly, they may be promoter sequences derived from the genome of a virus. In this regard, mention may be made, for example, of the ElA, MLP, CMV, RSV, etc. gene promoters. In addition, these expression sequences may be modified by adding activation sequences, regulatory sequences, etc. It may also be an inducible or repressible promoter.
Moreover, the nucleic acid may also comprise, in particular upstream of the gene of therapeutic interest, a signal sequence which directs the therapeutic product synthesized into the secretory pathways of the target cell. This signal sequence may be the natural signal sequence of the therapeutic product, but it may also be any other functional signal sequence or an artificial signal sequence. The nucleic acid may also comprise a signal sequence which directs the therapeutic product synthesized toward a particular compartment of the cell.
The compositions according to the invention may also comprise one or more adjuvants capable of associating with the transfecting compound/nucleic acid complexes and improving the-transfecting power thereof.
In another embodiment, the present invention therefore relates to compositions comprising a nucleic acid, a transfecting compound as described above and at least one adjuvant capable of associating with the transfecting compound/nucleic acid complexes and improving the transfecting power thereof. These adjuvants which make it possible to increase the transfecting power of the compounds according to the present invention are advantageously chosen from lipids (for example neutral lipids, in particular phospholipids), peptides (for example histone, nucleolin or protamine derivatives such as those described in WO 96/25508), proteins (for example proteins of the HMG type such as those described in WO 97/12051) and/or polymers (for example polymers which make it possible to turn the transfecting compound/nucleic acid formulations into "stealth" formulations, such as polyethylene glycol (PEG) introduced into the formulation on its own or in a form attached to a lipid in order to colloidally stabilize the transfecting compound/nucleic acid formulations, for example PEG-cholesterol). From this point of view, the compositions of the invention may comprise, as an adjuvant, one or more neutral lipids which in particular have the property of forming lipid aggregates. The term "lipid aggregate" is a generic term which includes liposomes of all types (both unilamellar and multilamellar) and also micelles or more amorphous aggregates.
More preferentially, the neutral lipids used in the context of the present invention are lipids containing two fatty chains. Particularly advantageously, use is made of natural or synthetic lipids which are zwitterionic or lacking ionic charge under physiological conditions. They may be chosen more particularly from dioleoylphosphatidylethanolamine (DOPE), oleoylpalmitoylphosphatidylethanolamine (POPE), distearoyl-, dipalmitoyl- and dimirystoylphosphatidylethanolamines and also the derivatives thereof which are N-methylated 1 to 3 times, phosphatidylglycerols, diacylglycerols, glycosyldiacylglycerols, cerebrosides (such as in particular galactocerebrosides), sphingolipids (such as in particular sphingomyelins) or asialogangliosides (such as in particular asialoGMl and asialoGM2).
According to a particularly preferred alternative, the lipid adjuvants used in the context of the present invention are chosen from DOPE, DOPC, cholesterol or the lipid derivatives of nonionic surfactants, such as PEG-cholesterol.
These various lipids may be obtained either by synthesis or by extraction from organs (for example the brain) or from eggs, using conventional techniques well known to those skilled in the art. In particular, the extraction of natural lipids may be carried out using organic solvents (see also Lehninger, Biochemistry).
Preferentially, the compositions of the invention comprise from 0.01 to 20 equivalents of adjuvant per equivalent of nucleic acid in mol/mol, and more preferentially from 0.5 to 5 molar equivalents.
According to another alternative, the adjuvants cited above make it possible to improve the transfecting power of the compositions according to the present invention; in particular, the peptides, the proteins or certain polymers, such as polyethylene glycol, may be conjugated to the transfecting compounds according to the invention, and not simply mixed. In particular, the PEG may be attached covalently to the lipid derivatives of aminoglycoside according to the present invention either at a remaining amine of the aminoglycoside or at the hydroxyl radicals of the aminoglycoside.
According to a particularly advantageous embodiment, the compositions according to the present invention also comprise a targeting element which makes it possible to direct the transfer of the nucleic acid.
This targeting element may be an extracellular targeting element which makes it possible to direct the transfer of the nucleic acid toward certain desired cell types or tissues (tumor cells, hepatic cells, hematopoietic cells, etc.). It may also be an intracellular targeting element which makes it possible to direct the transfer of the nucleic acid toward certain preferred cellular compartments (mitochondria, nucleus, etc.). The targeting element may be mixed with the transfecting compounds according to the invention and with the nucleic acids and, in this case, the targeting element is preferably attached covalently to a fatty aliphatic chain (at least 10 carbon atoms) or to a polyethylene glycol. According to another alternative, the targeting element is covalently attached to the transfecting compound according to the invention, either on one of the chemical functions which make up the spacer Y, or at the end of the lipid component (for example at the end of RI and/or R 2 when they represent fatty aliphatic chains), or directly on the aminoglycoside at one of the remaining amines or at the hydroxyl radicals. Finally, the targeting element may also be attached to the nucleic acid, as specified previously.
Among the targeting elements which can be used in the context of the invention, mention may be made of sugars, peptides, proteins, oligonucleotides, lipids, neuromediators, hormones, vitamins or derivatives thereof. Preferentially, they are sugars, peptides, vitamins or proteins such as, for example, antibodies or antibody fragments, cell receptor ligands or fragments thereof, receptors or receptor fragments.
For example, they may be ligands for growth factor receptors, for cytokine receptors, for receptors of the cellular lectin type or for folate receptors, or ligands containing an RGD sequence with an affinity for adhesion protein receptors such as integrins. Mention may also be made of transferrin receptors, HDL receptors and LDL receptors or the folate transporter.
The targeting element may also be a sugar which makes it possible to target lectins such as the receptors for asialoglycoproteins or for sialidized species, such as sialyl Lewis X, or an Fab antibody fragment or a single-chain antibody (ScFv).
A subject of the invention is also the use of the transfecting compounds according to the present invention, for transferring nucleic acids into cells in vitro, in vivo or ex vivo. More precisely, a subject of the present invention is the use of the transfecting compounds as defined in the context of the invention, for preparing a medicinal product intended to treat diseases, in particular diseases which result from a deficiency in a protein or nucleic acid product. The polynucleotide contained in said medicinal product encodes said protein or nucleic acid product, or constitutes said nucleic acid product, capable of correcting said diseases in vivo or ex vivo.
For uses in vivo, for example in therapy or for studying gene regulation or creating animal models of pathological conditions, the compositions according to the invention may be formulated with a view to topical, cutaneous, oral, rectal, vaginal, parenteral, intranasal, intravenous, intramuscular, subcutaneous, intraocular, transdermal, intratracheal, intraperitoneal, etc. administration. Preferably, the compositions of the invention contain a vehicle which is pharmaceutically acceptable for an injectable formulation, in particular for direct injection into the desired organ, or for topical administration (on skin and/or mucous membrane). They may in particular be sterile, isotonic solutions or dry compositions, in particular lyophilized compositions, which, by adding, as appropriate, sterilized water or physiological saline, allow injectable solutes to be made up. The doses of nucleic acids used for the injection and also the number of administrations may be adjusted depending on various parameters, and in particular depending on the method of administration used, on the pathological condition in question, on the gene to be expressed or on the desired duration of the treatment. With regard more particularly to the method of administration, it may be either a direct injection into the tissues, for example into the tumors, or an injection into the circulatory system, or it may involve treating cells in culture followed by their reimplantation in vivo, by injection or transplantation. The relevant tissues in the context of the present invention are, for example, muscles, skin, brain, lungs, trachea, liver, spleen, bone marrow, thymus, heart, lymph, blood, bones, cartilage, pancreas, kidneys, bladder, stomach, intestines, testicles, ovaries, rectum, nervous system, eyes, glands, connective tissues, etc.
Another subject of the present invention relates to a method for transferring nucleic acids into cells, comprising the following steps: bringing the nucleic acid into contact with a transfecting compound according to the present invention, so as to form a complex, and bringing the cells into contact with the complex formed in The invention also relates to a method for treating the human or animal body, comprising the following steps: bringing the nucleic acid into contact with a transfecting compound according to the present invention, so as to form a complex, and bringing the cells of the human or animal body into contact with the complex formed in The cells can be brought into contact with the complex by incubating the cells with said complex (for in vitro or ex vivo uses) or by injecting the complex into an organism (for in vivo uses). In general, the amount of nucleic acid intended to be administered depends on very many factors, such as for example the disease to be treated or prevented, the very nature of the nucleic acid, the strength of the promoter, the biological activity of the product expressed by the nucleic acid, the physical condition of the individual or of the animal (weight, age, etc.), the method of administration and the type of formulation. In general, the incubation is preferably carried out in the presence of, for example, from 0.01 to 1000 Ag of nucleic acid per 106 cells. For administration in vivo, nucleic acid doses ranging from 0.01 to 50 mg may, for example, be used. The administration may be carried out as a single dose or a repeated dose with periods in between.
When the compositions of the invention also contain one or more adjuvants as defined above, the adjuvant(s) is (are) mixed beforehand with the transfecting compound according to the invention and/or with the nucleic acid. Alternatively, the adjuvant(s) may be administered prior to administration of the nucleolipid complexes.
According to another advantageous alternative, the tissues may be subjected to chemical or physical treatment intended to improve the transfection. In the case of physical treatment, this may use electrical impulses as in the case of electrotransfer, or mechanical forces as in the case of "sodoporation".
The present invention thus provides a particularly advantageous method for transferring nucleic acids in vivo, in particular for the treatment of diseases, comprising the in vivo or in vitro administration of a nucleic acid encoding a protein, or possibly being transcribed into a nucleic acid, which is capable of correcting said disease, said nucleic acid being associated with a transfecting compound according to the invention under the conditions defined above.
The transfecting compounds of the invention are particularly useful for transferring nucleic acids into primary cells or into established lines. They may be fibroblast cells, muscle cells, nerve cells (neurons, astrocytes, glial cells), hepatic cells, hematopoietic cells (lymphocytes, CD34 cells, dendritic cells, etc.), epithelial cells, etc., in differentiated form or pluripotent form (precursors) Another subject of the present invention also relates to the transfection kits which comprise one or more transfecting compounds according to the invention and mixtures thereof. Such kits may be in the form of packaging containing compartments which can take various containers, such as for example vials or tubes.
Each of these containers comprises the various elements required to carry out the transfection, individually or mixed: for example one or more transfecting compound(s) according to the invention, one or more nucleic acid(s), one or more adjuvant(s), cells, etc.
Besides the arrangements above, the present invention also comprises other characteristics and/or advantages which will emerge from the following examples and figures, which should be considered as illustrating the invention without limiting the scope thereof. In particular, the Applicant provides, with no limitation being implied, an operating protocol and also reaction intermediates which can be used for preparing the transfecting compounds according to the invention. Of course, it is within the scope of those skilled in the art to use this protocol or intermediate products as a basis for developing similar processes with a view to producing these same compounds.
FIGURES
Figure 1: Reaction scheme for the synthesis of neomycin carbamoylcholesterol trifluoroacetate (cf. example a)Boc20, Et 3
N,
DMF/H
2 0, 60 0 C, 88%. b) 2,4,6-Triisopropylbenzenesulfonyl chloride, pyridine, 50%. c) HS-CH 2
-CH
2
-NH
2 NaOEt/EtOH, 46%. d)Cholesteryl chloroformate, Et 3 N, THF/DMF, 52%. e) Trifluoroacetic acid, T 0°C, 40 min, 98%.
Figure 2: dose-response curves of the in vitro transfection activity of the transfecting compound "KanaChol". The expression of the reporter gene is indicated as a function of the charge ratio of the lipoplexes formed with the plasmid DNA. The HeLa, HEK293 and COS cells were transfected in accordance with the protocol described in example 4 using lipoplexes prepared by mixing 5 gg of plasmid DNA expressing luciferase with the required amount of lipid. The data are expressed in relative light units (RLU) per mg of cellular proteins.
Figure 3: dose-response curves of the in vitro transfection activity of the KanaChol/DOPE (molar ratio 1:1) liposomes. The expression of the reporter gene is indicated as a function of the charge ratio of the lipoplexes formed with the plasmid DNA. The HeLa, HEK293 and COS cells were transfected in accordance with the protocol described in example 5 using lipoplexes prepared by mixing 5 gg of plasmid DNA expressing luciferase with the required amount of lipid to form lipoplexes characterized by the charge ratio indicated. The data are expressed in relative light units (RLU) per mg of cellular proteins.
Figure 4: cytotoxicity of the transfecting compound KanaChol. HeLa cells were transfected in accordance with the protocol described in example 4 using lipoplexes prepared by mixing 5 gg of plasmid DNA expressing luciferase with the amount of lipid required to form lipoplexes characterized by the charge ratio indicated. At 48 hours post-transfection, the cells were recovered and the toxicity was quantified using the total amount of cellular proteins in the cell lysate as an index of the number of cells, cell death producing a decrease in the extractable proteins. The total cellular proteins in the cell lysate is indicated as a function of the charge ratio of the lipoplexes.
The data are expressed as concentration of extractable cellular proteins in the cell lysate (at fixed volume).
Figure 5: cytotoxicity of the KanaChol/DOPE (molar ratio 1:1) lipsomes. HeLa cells were transfected in accordance with the protocol described in example using lipoplexes prepared by mixing 5 gg of plasmid DNA expressing luciferase with the amount of lipid required to form lipoplexes characterized by the charge ratio indicated. At 48 hours post-transfection, the cells were recovered and the toxicity was quantified using the total amount of cellular proteins in the cell lysate as an index of the number of cells, cell death producing a decrease in the extractable proteins. The total cellular proteins in the cell lysate is indicated as a function of the charge ratio of the lipoplexes.
The data are expressed as concentration of extractable cellular proteins in the cell lysate (at fixed volume).
Figure 6: Expression of luciferase in various cell lines transfected either with the transfecting compound KanaChol or with the KanaChol/DOPE liposomes. The various cell lines were transfected in accordance with the protocol described in example 6 using either KanaChol/DNA lipoplexes or KanaChol/DOPE/DNA lipoplexes (with a positive charge ratio of 3-5) prepared by mixing 5 pg of plasmid DNA expressing luciferase and the required amount of lipid to obtain a positive charge ratio of 3-5. The data are expressed in relative light units (RLU) per mg of cellular proteins.
Figure 7: Expression of luciferase in various cell lines transfected with the TGKC/DOPE (molar ratio 1:1) liposomes. The various cell lines were transfected in accordance with the protocol described in example 7 using TGKC/DOPE/DNA lipoplexes (with a positive charge ratio of 3-5) prepared by mixing 5 ug of plasmid DNA expressing luciferase and the required amount of lipid to obtain a positive charge ratio of 3-5. The data are expressed in relative light units (RLU) per mg of cellular proteins.
Figure 8: Expression of luciferase in various cell lines (HEK293, NIH 3T3, HeLa, COS, 16HBE) transfected with the NeoChol transfecting compound. Expression of the reporter gene is indicated at various charge ratios for the lipoplexes formed with the plasmid DNA. The various cell lines were transfected in accordance with the protocol described in example 8 using NeoChol/DNA lipoplexes prepared by mixing 5 pg of plasmid DNA expressing luciferase. The data are expressed in relative light units (RLU) per mg of cellular proteins.
Figure 9: Expression of luciferase in various cell lines (HEK293, NIH 3T3, HeLa, COS, 16HBE) transfected with the NeoChol/DOPE liposomes (molar ratio 1:1).
Expression of the reporter gene is indicated at various charge ratios for the lipoplexes formed with the plasmid DNA. The various cell lines were transfected in accordance with the protocol described in example 8 using NeoChol/DOPE/DNA lipoplexes prepared by mixing ug of plasmid DNA expressing luciferase. The data are expressed as relative light units (RLU) per mg of cellular proteins.
Figure 10: Expression of the CAT gene in the airways of mice following instillation of KanaChol/DOPE/DNA lipoplexes stabilized with Chol-PEG (hybrid molecule for which a polyethylene glycol is covalently attached to cholesterol) or NeoChol/DOPE/DNA stabilized with Chol-PEG. These liposomes, characterized by a positive charge ratio of 3.75 for KanaChol/DOPE/DNA lipoplexes stabilized with Chol-PEG or 3.3 for NeoChol/DOPE/DNA lipoplexes stabilized with Chol-PEG and a cholesterol- PEG/DNA weight/weight ratio of 2, were used to deliver a total dose of 100 kg of plasmid DNA expressing the CAT gene. Intranasal instillation was performed, and then the trachea and lungs of the mice treated were removed in order to measure the CAT expression according to the method described in example 9. The data are expressed in ng of CAT protein 100 mg of total cellular proteins.
00 N Figure 11 :Schematic representation of the plasmid pCMV-Luc.
SFigure 12:Schematic representation of the plasmid pCIK-CAT.
Figure Comparison of the transfection efficiency of aminoglycoside lipidic derivatives with commercial transfecting compounds.
Figure 14: Comparison of the efficiency of transfection into COS-7 cells of other aminoglycoside lipidic derivatives and commercial transfecting compound Escort
V.
c Figure 15: Comparison of the efficiency of transfection of aminoglycoside lipidic derivatives of a CAT encoding DNA plasmid into Mesenchymal stem cells.
EXAMPLES
The reagents and catalysts such as triethylamine, trifluoroacetic acid, p-toluenesulfonic acid, benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), dicyclohexylcarbodiimide (DCC), carbon disulfide, palladium-on-charcoal, tetradecylamine, di-tert-butyl dicarbonate, 4dimethylaminopyridine, diisopropylethylamine, norbornene-2,3-dicarboximide, 2-(trimethylsilyl)ethyl p-nitrophenyl carbonate and cholesteryl chloroformiate are commercially available, as is Kanamycin A. In addition, N,N'-bis-tert-butoxycarbonylthiourea was prepared in accordance with the procedure published in Synth. Commun. (1993), 23, pp. 1443-1445 and neomycin amine was prepared according to Tor et al. Am. Chem. Soc. 2000, 122, 980-981).
The proton nuclear magnetic resonance (1H NMR) spectra were recorded on a Bruker 200 MHz spectrometer. The chemical shifts are expressed in ppm (parts per million) and the multiplicities are expressed using the usual abbreviations.
The plasmids used are: pCMV-Luc described in the publication by Patel et al. (BBRC, 2001, 6, pp.
536-543), which contains the luc gene encoding luciferase under the control of the CMV immediate early promoter of the cytomegalovirus. This plasmid is represented in figure 11. It was constructed by subcloning the CMV promoter (from the pcDNA3 plasmid of Invitrogen) upstream of the luc gene in the plasmid pGL2-Basic (Promega). It is 6255 bp in size.
pCIK-CAT (for the transfections in vivo) obtained from D. Giel (Oxford, UK), which is described by Pitard et al. Gene Med.
2001, 3, 478-487). It was constructed by subcloning the E. coli CAT gene in the plasmid pCI (Promega). This plasmid is represented in figure 12. It is 4697 bp in size.
Example 1: Synthesis of 30 [6'-kanamycincarbamoyl]cholesterol ("KanaChol") a) Synthesis of [(1,3,3"-triamino)-6'-N- (benzyloxycarbonyl)]kanamycin A N-Benzyloxycarbonyloxy-5-norbornene-2,3dicarboximide (5.18 g; 16.5 mmol) and triethylamine (1.67 g; 16.5 mmol) are added to a solution of kanamycin A in the form of free base (8 g; 16.5 mmol) in a mixture of dimethyl sulfoxide (800 ml) and water (80 ml). After stirring overnight at room temperature, a considerable precipitate has formed and analysis of the reaction mixture by TLC (thin-layer chromatography) reveals the presence of unreacted products. Water (640 ml) is then added again until the mixture becomes homogeneous, followed by norbornene-2,3-dicarboximide (2.6 g; 8.3 mmol). After 4 days of stirring, the solvents are evaporated off under vacuum and the residue is chromatographed on a silica column with an eluent ranging from a dichloromethane/methanol/ammonia mixture to a methanol/ammonia mixture. By evaporating off the solvents from the fractions concerned, the expected compound is recovered (7.15 g; b) Synthesis of [(1,3,3"-triaza- (trimethylsilylethoxycarbonyl)]-[6'-N- (benzyloxycarbonyl)]kanamycin A ("Kana-tri[Teoc]mono[Cbz]") Triethylamine (0.25 g; 3 equivalents; 2.42 mmol) and mixed 2-(trimethylsilyl)ethyl pnitrophenyl carbonate (0.92 g; 4 equivalents; 3.23 mmol) were added to a solution of Kana-mono[Cbz] g; 0.81 mmol) in a water (7 ml)/dioxane (16 ml) mixture. The mixture is stirred at 55 0 C for 48 hours and, after having been concentrated, the suspension obtained is poured into butanol presaturated with water ml). After several washes with a 1N sodium hydroxide solution (800 ml) and with a saturated sodium chloride solution, the butanolic phase is evaporated to dryness. The desired product is obtained in the form of a yellow powder (0.73 g; 86%) by adding a mixture of methanol and acetone to the residue and concentrating the solution thus obtained.
c) Synthesis .of triaza(trimethylsilylethoxycarbonyl)]kanamycin A ("Kana-tri[Teoc]-NH 2 Palladium-on-charcoal (Pd/C at 10%; 0.3 g) is added to a degassed solution of Kana-tri[Teoc]mono[Cbz] (0.3 g; 0.29 mmol) in methanol (25 ml) and a stream of hydrogen is bubbled into the mixture for 1 hour. The latter is again stirred overnight under a hydrogen atmosphere, and the suspension is then filtered over celite and evaporated to dryness. The desired product in the form of a white solid (0.23 g; is thus obtained.
d) Synthesis of triaza(trimethylsilylethoxycarbonyl)]-[6'-N-(3oxocarbonylcholesteryl)]kanamycin A ("Kana-tri[Teoc]- Chol") Triethylamine (1.5 equivalents; 0.017 g; 0.16 mmol) and cholesteryl chloroformiate equivalents; 0.074 g; 0.16 mmol) are added to a solution of Kana-tri[Teoc]-NH 2 (0.1 g; 0.11 mmol) in a mixture of tetrahydrofuran (5 ml) and dimethylformamide (2 ml). The mixture is stirred at room temperature for 48 hours before being concentrated under reduced pressure until only the dimethylformamide remains.
Adding water to this solution causes a white precipitate to form, which is filtered (0.12 g; 83%).
e) Synthesis of 1,3,3"-triamino-6'-N-(3oxocarbonylcholesteryl)kanamycin A trifluoroacetate ("Kanachol") The Kana-tri[Teoc]-Chol obtained in the previous step (0.070 g; 0.053 mmol) is suspended for minutes in trifluoroacetic acid maintained at 0°C in an ice bath. After having been returned to room temperature, the mixture is concentrated to dryness.
The residue is taken up in methanol and again concentrated to dryness. By repeating this procedure several times, the Kanachol is obtained in the form of a white solid (0.063 g; 97%).
'H NMR (CD30D): 6 (ppm) 5.32 1H, anomeric 5.09 1H, H of cholesterol); 4.97 1H, anomeric H); 4.30 1H, H of cholesterol); 3.85-2.98 16H, diverse protons of the glycosidic rings); 2.30-0.81 (m, 44H, diverse protons of the glycosidic rings and of the cholesterol nucleus); 0.63 3H, CH 3 of cholesterol).
Example 2: Synthesis of 30 triguanidino)kanamycin-carbamoyl]cholesterol ("TGKC") a) Synthesis of [l,3,3"-triaza(N,N'-bis-tertbutoxycarbonyldiaminomethylene)-6'-N-(3oxocarbonylcholesteryl)kanamycin A ("Kana-tri[GuanBoc]- Chol") Triethylamine (30 equivalents; 0.36 g; 3.63 mmol), N,N'-bis-tert-butoxycarbonylthiourea equivalents; 0.117 g; 0.42 mmol) and mercuric chloride equivalents; 0.115 g; 0.42 mmol) are added successively to a solution of Kanachol, obtained according to the protocol of the example above (0.15 g; 0.12 mmol), in dimethylformamide (10 ml). The mixture is stirred at room temperature and under an inert atmosphere for 48 hours. The solution is then poured into a mixture of water and ethyl acetate and the aqueous phase is extracted 4 times with ethyl acetate.
After washing with a saturated sodium chloride solution and drying over sodium sulfate, the pooled organic fractions are concentrated to dryness. The desired product is obtained in the form of a white powder (0.1 g; 51%).
b) Synthesis of the triflate salt of triaza(N,N'-bisdiaminomethylene)-[6'-N-(3oxocarbonylcholesteryl)kanamycin A ("Kana-tri[Guan]- Chol" or "KTGC") The Kana-tri[GuanBoc]-Chol obtained in the previous step (0.060 g; 0.037 mmol) is suspended in trifluoroacetic acid maintained in an ice bath. After hours at 0°C and then a return to room temperature, the mixture is concentrated to dryness. The red-brown residue is taken up in methanol and then again concentrated to dryness. This operation is repeated 3 times. Pentane is then added and the mixture is subjected to sonication so as to obtain a fine suspension, which is then centrifuged. 0.030 g of pure KTGC is thus recovered (yield: 1H NMR (D 2 5 (ppm) 5.48 1H, anomeric 5.05 (m, 1H); 3.97 1H, H of cholesterol); 3.70-2.60 (m, diverse protons of the glycosidic rings); 2.18-0.80 (m, diverse protons of the glycosidic rings and of the cholesterol nucleus).
Example 3: Synthesis of neomycin carbamoylcholesterol ("NeoChol") The amino glycoside neomycin is grafted onto the Y-L assembly using an amine function originating from a modification carried out according to Tor et al.
Am. Chem. Soc. 2000, 122, 980-981) The reaction scheme for the synthesis of NeoChol is given in figure 1.
a) Synthesis of N-hexa-tert-butyloxycarbonyl NeoChol Triethylamine (14 ml; 0.10 mmol; 1.2 equivalents) and cholesteryl chloroformate (43.1 mg; 0.10 mmol; 1.2 equivalents) are added to a solution of neomycin amine (102 mg, 0.08 mmol, 1 equivalent), prepared according to Tor et al. Am. Chem. Soc. 2000, 122, 980-981), in a mixture of tetrahydrofuran (6 ml) and dimethylformamide (2 ml). The reaction mixture gradually becomes cloudy and is stirred overnight. The volatile solvents are then evaporated off under vacuum and the residue is chromatographed on a silica column with a 90/5/5 dichloromethane/methanol/ethyl acetate mixture as eluent. By evaporating the solvents from the fractions concerned, the expected product is recovered in the form of a white solid.
Rf 0.45 (dichloromethane/methanol 9/1; thin layer chromatography) SH NMR(200 MHz, CDC1 3 8 (ppm) 6.15 (broad 5.90 (m, 1 5.35 2H); 5.36 1H, Chol); 5.25-4.86 (m, 4.60-3.20 15H); 3.10 1H); 2.86 2H); 2.69 2H); 2.50-1.72 10H); 1.72-0.84 87H); 0.71 3H, CH 3 Chol).
Mass (MALDI-TOF): [MNa 1708.98.
B) Synthesis of (5"-aminoethylsulfanyl) neomycin carbamoylcholesterol trifluoroacetate The N-hexa-tert-butyloxycarbonyl NeoChol obtained in the previous step (60 mg; 0.035 mmol; 1 equivalent) is suspended in trifluoroacetic acid (2 ml) placed in an ice bath. After 50 minutes at 0°C, the mixture is concentrated to dryness. The residue is taken up in methanol and is then again concentrated to dryness.
This operation is repeated three times and the solids residue is then dissolved in water and lyophilized; NeoChol is thus recovered in the form of a cottony white powder (59.6 mg, 95.2%).
H NMR (200 MHz, [D4]methanol): 6 6.05 (broad s, 1H); 5.46-5.31 3H); 4.43-4.29 4H); 4.21-3.82 (m, 3.67-3.11 13H); 2.89-2.60 3H); 2.58-2.25 3H); 2.20-1.73 7H); 1.72-0.84 33H); 0.71 3H, CH3 Chol).
Mass (MALDI-TOF): [MH 1086.83; [MNa'] 1108.80.
Example 4: Dose-response curves of the in vitro transfection of the transfecting compound KanaChol in aqueous medium The aim of this example is to illustrate the ability of the transfecting compounds according to the invention to transfect cells in vitro.
This study was carried out for lipoplexes comprising various amounts of KanaChol: 6.6, 13.2, 33, 66 or 132 nmol of KanaChol per 5 gg of DNA. In order to determine the theoretical mean charge ratio, it was considered that 1 .g of DNA represents 3 nmol of negative charges and that 3 amine groups of kanamycin are protonated at neutral pH during the formation of the lipoplexes and the transfection. In fact, electrophoretic gel shift studies for the kanamycin complexed with nucleic acids suggest that the mean positive charge of the KanaChol is rather 2-3.
Preparation of the KanaChol/DNA lipoplexes: the KanaChol obtained according to example 1 is dissolved in a 20 mM Hepes buffer solution (pH 7.4) at a positive charge concentration of 20 mM (considering that 3 amine functions are protonated at neutral pH).
The lipoplexes are then prepared in accordance with the protocol described by Vigneron et al. (PNAS, 93, pp.
9682-9686, Sept. 1996) or by Patel et al. (Biochem. and Biophys. Res. Comm., 281, pp. 536-543, 2001).
Cell culture: HeLa cells (American type Culture Collection (ATCC) Rockville, MD, USA) derived from a human cervical epithelium carcinoma are cultured in the presence of a medium of the MEM (minimum essential medium) type supplemented with 10% of fetal calf serum and antibiotics. The medium and the additives come from Gibco/BRL Life Technologies (Gaithersburg, MD, USA). The cells are cultured in flasks at 370C and at 5% of carbon dioxide in an incubator. The same procedure is used for the HEK293 and COS cells.
Transfection: one day before transfection, the HeLa cells are transferred into 6-well plates with approximately 250,000 cells per well. These dilutions represent approximately 80% confluencing after 24 hours. For the transfection, the cells are washed twice and incubated at 37 0 C with 500 Ml of medium without serum. 500 gl of complexes containing 5 pg of plasmid DNA are added to each well (the complexes are prepared at least 30 minutes before being added to the wells).
After six hours at 37 0 C, the plates without serum are supplemented with 10% of FCS ("Fetal Calf Serum").
All of the plates are placed at 37 0 C and at of carbon dioxide for 24 hours.
This protocol is similar to those described by Vigneron et al. (PNAS, 93, pp. 9682-9686, Sept.
1996) or by Patel et al. (Biochem. and Biophys. Res.
Comm., 281, pp. 536-543, 2001).
Determination of luciferase activity: Briefly, the transfected cells are washed twice with 500 pg of PBS (phosphate buffer) and then lysed with 250 l of reagent (25 mM triphosphate, pH 7.8 8 mM MgC1 2 1 mM dithiothreitol 15% glycerol 1% triton X-100). The lysate is then clarified by centrifugation minutes at 15 0 C) in a microcentrifuge.
A 20 il aliquot of supernatant of the centrifuged lysate is diluted in 100 pg of lysis buffer, to which 4 /l of 25 mM ATP (Sigma) and 20 /1 of mM luciferin (Sigma) are added. The samples are then placed in a Lumet LB9501 luminometer (Berthold, Nashua, NH) and the light emission integration value is measured for 10 seconds.
The luciferase activity is thus expressed in Relative Light Units and standardized with the sample protein concentration obtained using a Biorad kit.
This protocol is similar to that described by Vigneron et al. (PNAS, 93, pp. 9682-9686, Sept.
1996) or by Patel et al. (Biochem. and Biophys. Res.
Comm., 281, pp. 536-543, 2001).
The results for the 3 cell lines summarized in figure 2 show high expression levels with optimum transfection efficiency for the lipoplexes which have a theoretical mean charge ratio of approximately 5. The transfection is highest in the COS cell line.
A control was also carried out with complexes formed between kanamycin (not attached to a cholesterol derivative) and the DNA: no transfection was observed.
These data therefore demonstrate that the KanaChol makes it possible to carry out efficient transfection of DNA into cells in vitro. These results are also coherent with the hypothesis that the transfection is related to the electrostatic interaction between the positive lipoplexes and the cell surface, which is negative overall.
Figure 2 also shows that the transfection efficiency decreases for very high charge ratios (greater than approximately This decrease may reflect a certain toxic effect of cationic lipids in general, and therefore of the KanaChol in particular, when they are used in large amounts.
Thus, the cytotoxicity of the KanaChol was also measured at various charge ratios with the DNA.
The toxicity was quantified using the total amount of cellular proteins in the cell lysate per well as an index of the number of cells. A decrease in the total amount of cellular proteins in the cell lysate per well corresponds to a decrease in the number of cells and, consequently, reflects the existence of a certain toxicity of the KanaChol/DNA lipoplexes with respect to the cells.
Determination of the protein level: the protein level was determined using the Biorad kit according to a protocol identical to that described by Oudrhriri et al. (PNAS, 94, pp. 1651-1656, 1997), and in accordance with the manufacturer's instructions.
The results summarized in figure 4 show a decrease in the total number of extractable cellular proteins at high charge ratio, i.e. an increase in the cytotoxicity in parallel with the increase in the KanaChol concentrations. Thus, the decrease in the transfection activity at high charge ratios in the 3 cell lines tested may be related to the existence of a certain toxicity of the KanaChol used in very large amounts.
Example 5: Dose-response curves of the in vitro transfection of the KanaChol/DOPE liposomes The aim of this example is to illustrate the ability of the transfecting compounds according to the invention to transfect cells in vitro, when they are formulated in the form of liposomes with neutral lipids.
Cationic lipids are often formulated in the form of liposomes with neutral lipid DOPE. It is in fact thought that the use of DOPE, due to its fusogenic properties, would aid transfection by facilitating the exit of the lipoplexes from the endocytic vesicles in which they are internalized. It has thus been shown by Felgner et al. Biol. Chem., 1994, 269, pp. 2550- 2561), for a series of cationic lipids, that formulating them with 50% of DOPE makes it possible to increase the transfection efficiency 2- to compared to formulations without zwitterionic lipid.
For this reason, KanaChol/DOPE (1:1 molar) liposomes were prepared in the following way: a mixture of KanaChol and DOPE (molar ratio 1:1) in chloroform is evaporated under vacuum and resuspended in a 20 mM Hepes buffer solution (pH The final concentration of lipids is 5 mg/ml. The mixture is then sonicated for minutes using a Branson Sonifier 450 ultrasound machine equipped with a Sonifier Cell Disruptor terminal, so as to obtain liposomes. The resulting solution is cooled to room temperature before filtration through a 0.22 im filter (Millex GS, Millipore).
In the same way as the example above, this study was carried out for liposomes comprising various amounts of KanaChol, so as to measure the transfection efficiency at variable theoretical mean charge ratios, in the 3 cell lines HeLa, HEK293 and COS.
The results summarized in figure 3 show high levels of luciferase expression for the 3 cell lines.
These transfection levels are entirely comparable with those obtained with the formulations of KanaChol alone (without DOPE), which may be explained by the fact that the 3 cell lines used are very easily transfectable. On the other hand, it is observed that there is no clear decrease in the transfection activity at high charge ratios when KanaChol/DOPE/DNA liposomes are used.
Thus, the cytotoxicity of the KanaChol/DOPE liposomes was also measured at various charge ratios with the DNA, according to a protocol similar to that described in the example above. The data summarized in figure 5 indicate that these liposomal formulations show no apparent toxicity at high charge ratios. It therefore appears that the KanaChol, used in liposomal formulation, is a transfection vector which is both efficient and nontoxic.
Example 6: Spectra for the in vitro transfection activity of the transfecting compound KanaChol and of the KanaChol/DOPE liposomes The aim of this example is to illustrate the ability of the transfecting compounds according to the invention to transfect other cell types in vitro, whether they are used alone or in the form of a liposome with DOPE.
The in vitro transfection experiments carried out in examples 4 and 5 were again carried out in a similar way, but with other less conventional cell lines (species and specificity of each cell line are indicated in figure The KanaChol/DNA and KanaChol/DOPE/DNA formulations are used at charge ratios of between 3 and 5 (optimum values as defined in examples 4 and The results obtained are summarized in the table of figure 6.
It appears that the KanaChol/DOPE (molar ratio 1:1) formulation induces high transfection efficiency for all the cell lines, the KanaChol used alone (without DOPE) being less efficient overall, in particular in the cell lines 16HBE and HepG2. It therefore appears that the use of DOPE would have a beneficial effect on transfection efficiency.
Example 7: In vitro transfection activity of the TGKC/DOPE liposomes The aim of this example is to illustrate the ability of the polyguanidylated transfecting compounds according to the invention (formulated in the form of liposomes) to transfect cells in vitro.
TGKC/DOPE (molar ratio 1:1) formulations obtained in a similar way to the protocol described in example 5 are thus used to transfect various cell lines (COS, HeLa, NIH3T3 and MITC) in vitro, according to transfection methods similar to those described in the previous examples. The charge ratio of the TGKC/DOPE/DNA lipoplexes was fixed between 3 and i.e. at values which had previously proved to be optimal with the KanaChol. Naturally, in order to determine the theoretical mean charge ratio, it was considered that the 3 guanidinium groups of the TGKC are positively charged at neutral pH (due to the high pKa of guanidinium functions).
The results summarized in figure 7 clearly show that the TGKC/DOPE liposomes make it possible to efficiently transfect the various cell lines tested.
Example 8: In vitro transfection activity spectra for the NeoChol transfecting compound and for the NeoChol/DOPE liposomes The aim of this example is to illustrate the ability of the transfecting compounds according to the invention to transfect various cell types in vitro, whether they are used alone or in the form of a liposome with DOPE.
The in vitro transfection experiments performed in examples 4, 5, 6 and 7 were carried out in a similar manner using the NeoChol/DNA and NeoChol/DOPE/DNA formulations at various charge ratios (between 1.3 and 26 for NeoChol/DNA and between 0.66 and 26 for NeoChol/DOPE/DNA) and in a series of 5 cell lines (HeLa, NIH 3T3, HEK293, COS and 16HBE). The lipoplexes and the liposomes were prepared in a manner similar to the protocol described in examples 4 and 5 (estimating that 5 amino functions are protonated for NeoChol at neutral pH). The results obtained are summarized in figures 8 and 9.
The results summarized in figure 8 clearly show that the NeoChol/DNA formulations make it possible to efficiently transfect the various cell lines tested.
It appears that the NeoChol/DOPE formulation (molar ratio 1:1) induces a high transfection efficiency for all the cell lines, the NeoChol used alone (without DOPE) appearing overall to be a little less efficient, in particular in the 16HBE cell line (except for the high charge ratios). It therefore appears that the use of DOPE would have a beneficial effect on the transfection efficacy.
Example 9: In vivo gene transfer into the airways of mice using the KanaChol/DOPE/Chol-PEG liposomes This example illustrates the ability of the transfecting compounds according to the invention to transfect DNA into cells in vivo.
The in vivo gene transfer was carried out with 50 il (per dose) of transfecting medium containing the KanaChol/DOPE/DNA or NeoChol/DOPE/DNA lipoplexes stabilized with Chol-PEG, in the airways of female BALB/c mice weighing 30 g (intranasal administration).
Each animal received 3 doses, approximately 4 hours apart, i.e. a total amount of 100 jg of pCIK-CAT plasmid DNA.
The formulations used were prepared in the following way: KanaChol/DOPE liposomes are prepared according to the protocol described in example 6. A solution of steric stabilizer Chol-PEG (a cholesterol attached to a polyethylene glycol chain containing approximately 100 oxyethylene units) is then added immediately before mixing with the pCIK-CAT plasmid DNA in aqueous solution. The DNA concentration is thus approximately 0.6 mg/ml and the positive charge ratio is 3.75. The final Chol-PEG/DNA ratio is then 2 (weight/weight). The use of Chol-PEG allows the production of colloidally stable solutions which makes it possible to have very high transfection efficiency in the airways of mice in vivo via intranasal instillation of the liposomal formulations. The NeoChol/DOPE/Chol-PEG formulations are prepared in the same way, but the positive charge ratio used is 3.3 for these formulations.
The reporter gene used in the present case is the CAT ("Escherichia Coli chloramphenicol acetyltransferase") gene. The administration into the airways is carried out by intranasal instillation. 48 hours post-transfection, the animals are killed and the lungs and trachea are removed separately for analysis.
The tissue pieces are placed in a TEN buffer (40 mM of Tris-HCl, 1 mM of EDTA and 150 mM of sodium chloride, pH 7.8) and agitated on ice for approximately seconds using an Ultra-Turrax T25 agitator (Fisher 00 0 Bioblock Scientific, Strasbourg, France). The cells are then lysed with 3 N freezing-thawing cycles and a clear supernatant is obtained by centrifugation. The d CAT concentration is determined using a CAT ELISA assay carried out in accordance with the manufacturer's (Boehringer Mannheim) instructions. The 0 5 CAT levels are expressed in ng of CAT protein per 100 mg of total proteins, the protein concentration being determined using a Bio-Rad assay.
SThe table of figure 10 shows the levels of expression of the CAT gene Sobtained in the homogenates of trachea and of lung. The expression of the CAT gene is highest in the lung. Figure 10 also indicates that very low levels of a 10 expression are obtained after administration of identical doses of "naked" DNA S(i.e. nonformulated DNA). These results suggest that, under the conditions of the experiment, the KanaChol/DOPE and NeoChol/DOPE liposomes allow a transfection efficiency in vivo, in airways of mice, which is greater than that obtained with naked DNA. The expression levels obtained using the NeoChol/DOPE liposomes are of the same order of magnitude as those obtained using the KanaChol/DOPE liposomes. These results are also entirely similar to those which had been obtained with BGTC/DOPE formulations (described in application WO 97/31935), these being formulations which had proved to be most particularly efficient and advantageous for transfecting airways (Densmore et al., J. of Gene Med., 1999, Vol Comprises/comprising and grammatical variations thereof when used in this specification are to be taken to specify the presence of stated features, integers, steps or components or groups thereof, but do not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.
00 Example 10: TRANSFECTION EFFICIENCY OF. AMINOGLYCOSIDE LIPIDIC DERIVATIVES ACCORDING TO THE INVENTION COMPARED TO COMMERCIAL TRANSFECTING COMPOUNDS 1. Materials The following aminoglycoside derivatives according to the invention were tested for their transfection efficiency and compared to commercial compounds: DiOleylamine A-Succinyl-Tobramycine (DOST),
OH
HOO H2N >~OH 0 HN H 2 N NH -r NH 2 N 0 .4 CF 3 C00H DiOleylamine A-Succinyl-Kanamycine (DOSK), .3 CF 3
COOH
DiOleylamine A-Succinyl-Paromomycine (DOSP)
OH
HO
OH
0
NH
OH .4 CF 3
COOH
DiOleylamine A-Succinyl-Neomycine (DOSN) 00 CLoo NH2 OI H (c HO- s HI o 2 sH, O OH rNH 2 04OH .6 CF 3 COOH HN OH Commercial compounds used for comparison were compounds named r n Lipofectamine TM (a lipopolyamine compound), EscortTM V (a poly(ethyleneimine) Scompound) and FuGENE 6® II. Comparison of the transfection efficiency of DOSP aminoglycoside lipidic derivative with commercial transfecting compounds Mesenchymal stem cells, primary neural cells, Madin Dardy Canine Kidney cell (MDCK), Human cervix adenocarcinoma cell (HeLa), and Immortalized Human Hepatocytes (IHH) were transfected in a suitable medium with a DNA plasmid coding for expression of luciferase using DOSP aminoglycoside lipidic derivative, or commercial cationic lipids transfecting compounds LipofectamineTM (a lipopolyamine compound), EscortTM V (a poly(ethyleneimine) compound) and FuGENE 6®.
Luciferase expression was then monitored in the various cell types transfected with the distinct transfecting compounds. These experiments were carried out as described hereinbefore or in the article "Kanamycin A-derived cationic lipids as vectors for gene transfection" Sainlos Hauchecorne M., Oudrhiri Zertal-Zidani Aissaoui Vigneron JP., Lehn JM., Lehn P.
(Chembiochem. 2005 Jun;6(6): 1023-33).
Results of the comparison are shown in Figure 13 A-E.
In all cases, the transfection efficiency of DOSP, an aminoglycoside lipidic derivative according to the invention, was much higher than even the best other cationic lipid transfecting compound.
Nevertherless, all of the commercially tested compounds are well-known transfecting cationic lipid transfecting compounds comprising a cationic moiety binding to nucleic acids.
00 SIIIll. Comparison of the transfection efficiencies of other aminoglycoside c1 lipidic derivative with commercial transfecting compound Escort V cs In addition to the experiments conducted with DOSP (aminoglycoside C paromomycine), experiments were performed using other aminoglycoside 0 5 moieties and are reported below.
Following the same procedures as outlined above, Cos-7 cells were Stransfected with 1 ig of plasmid DNA encoding luciferase complexed with various lipidic aminoglycoside derivatives. Luciferase activity was measured 24 hours t' after transfection.
S 10 Figure 14 indicates that for luciferase encoding DNA transfection into C- COS-7 cells, lipid derivatives of Kanamycine (DOSK) or Neomycine (DOSN) allow for a transfection efficiency similar to that of the paromomycine lipid derivative (DOSP) used in the experiments described above and significantly higher than the commercial transfection agent EscortTM V.
The high level of DNA transfection using various compounds according to the invention, such as lipid derivatives of Paromomycine (DOSP), Kanamycine (DOSK), Neomycine (DOSN) and Tobramycine (DOST), was further confirmed by testing Choramphenicol Acetyl Transferase (CAT) encoding DNA transfection of mesenchymal stem cells.
Mesenchymal stem cells were transfected in 24 well-plates with 1lig plasmid DNA encoding Choramphenicol Acetyl Transferase (CAT) complexed with various lipidic aminoglycoside derivatives. CAT was measured by ELISA 24 hours after transfection.
Figure 15 indicates that all of the compounds according to the invention tested are able to efficiently transfect mesenchymal stem cells with a CAT encoding DNA plasmid with a similar efficiency.
Claims (31)
1. Transfecting compound of general formula A-Y-L (I) in which: A represents an aminoglycoside or its polyguanidylated derivative, v Y represents a spacer, and L represents: t' either a radical -(R1)R 2 with R, and R 2 which represent, independently of O 10 one another, a hydrogen atom or a fatty aliphatic chain or R 1 or R 2 is absent, it being understood that at least one of R 1 and R 2 represents a fatty aliphatic chain chosen from alkyl radicals containing 14, 16, 18, 20 or 22 carbon atoms and optionally 1, 2 or 3 unsaturations, or a radical -N-R 3 or -O-R 3 with R 3 which represents a steroidal derivative, where appropriate, in the form of an isomer, of a mixture or of a salt.
2. Transfecting compound according to Claim 1, characterized in that said aminoglycoside is chosen from amikacin, arbekacin, deoxyhydrostreptomycin, destomycin A, dibekacin, dihydrostreptomycin, genticin, gentamycin, hygromycin, isepamycin, kanamycin, micronomycin,' paromomycin, ribostamycin, streptomycin, streptonicozide, neomycin, tobramycin, sisomycin or semi-synthetic aminosides.
3. Transfecting compound according to Claims 1 or 2, characterized in that said spacer comprises one or more chemical functions chosen from alkyls having 1 to 6 carbon atoms, ketone, ester, ether, amino, amide, amidine, carbamate or thiocarbamate functions, glycerol, urea, thiourea or aromatic rings.
4. Transfecting compound according to Claim 3, characterized in that said spacer is chosen from the radicals of formula: -NH-C(O)-CH 2 -CH 2 or: -(CH 2 -)i-W-(CH 2 )j- in which i, j and k are integers chosen between 1 and 6 inclusive, and W and W' are groups, which may be identical or different, chosen from ketone, ester, ether, 00 O amino, amide, amidine, carbamate or thiocarbamate functions, glycerol, urea, C1 thiourea or aromatic rings. Transfecting compound according to any one of Claims 1 to 4, N 5 characterized in that said fatty aliphatic chain(s) is (are) chosen from the aliphatic radicals -(CH 2 11 CH 3 -(CH 2 13 CH 3 (CH 2 15 CH 3 and -(CH 2 )17CH 3 ti 6. Transfecting compound according to any one of claims 1 to 4, characterized in that said steroidal derivative is: a polycyclic compound of the cholestane type. 0 7. Transfecting compounds according to Claim 6, characterized in that said steroidal derivative is chosen from cholesterol, cholestanol, cholestan-6-p-ol, cholic acid, cholesteryl formiate, cholestanyl formiate, cyclo-5-a-cholestan-6-p-yl formiate, cholesterylamine, 6-(1,5-dimethylhexyl)- 3a,5a-dimethylhexadecahydrocyclopenta[a]cyclopropa[2,3]cyclopenta[1,2-f] or cholestanylamine.
8. Transfecting compound according to claim 1, characterized in that it is 3p[6'-kanamycin-carbamoyl]cholesterol.
9. Transfecting compound according to claim 1, characterized in that it is 3p[6'-(1,3,3"-triguanidino)kanamycin-carbamoyl]cholesterol.
10. Transfecting compound according to claim 1, characterized in that it is aminoethylsulfanyl) neomycin carbamoylcholesterol.
11. Composition, characterized in that it comprises a transfecting compound according to one of Claims 1 to 10, and a nucleic acid.
12. Composition according to Claim 11, characterized in that the nucleic acid is a deoxyribonucleic acid or a ribonucleic acid.
13. Composition according to Claim 11 or 12, characterized in that said nucleic acid comprises one or more genes of therapeutic interest under the control of regulatory sequences. 00
14. Composition according to any one of Claims 11 to 13, characterized in that C said nucleic acid is an antisense sequence or gene. Composition according to one of Claims 11 to 14, characterized in that it c 5 also comprises one or more adjuvants.
16. Composition according to Claim 15, characterized in that said adjuvant(s) In is (are) chosen from lipids, peptides, proteins or polymers.
17. Composition according to Claim 16, characterized in that said adjuvant(s) Sis (are) chosen from neutral lipids.
18. Composition according to Claim 17, characterized in that said neutral lipid is chosen from natural or synthetic lipids which are zwitterionic or lacking ionic charge under physiological conditions.
19. Composition according to Claim 18, characterized in that said neutral lipid is chosen from dioleoylphosphatidylethanolamine (DOPE), oleoyl- palmitoylphosphatidylethanolamine (POPE), distearoyl-, dipalmitoyl- and dimirystoylphosphatidylethanolamines and also the derivatives thereof which are N-methylated 1 to 3 times, phosphatidylglycerols, diacylglycerols, glycosyldiacylglycerols, cerebrosides (such as in particular galactocerebrosides), sphingolipids (such as in particular sphingomyelins), asialogangliosides (such as in particular asialoGM1 and asialoGM2), DOPC and cholesterol. Composition according to Claim 16, characterized in that said adjuvant is polyethylene glycol (PEG) or PEG-cholesterol.
21. Composition according to one of Claims 11 to 20, characterized in that it also comprises an extracellular or intracellular targeting element.
22. Composition according to Claim 21, characterized in that said targeting element is chosen from sugars, peptides, proteins, oligonucleotides, lipids, neuromediators, hormones, vitamins or derivatives thereof.
23. Composition according to Claims 21 or 22, characterized in that said targeting element is covalently attached to a fatty alkyl chain containing at least carbon atoms or to a polyethylene glycol (PEG). 00
24. Composition according to Claim 21, characterized in that said targeting Selement is covalently attached either to the transfecting compound according to one of Claims 1 to 10, or to the nucleic acid. c 5 25. Composition according to one of Claims 11 to 24, characterized in that it also comprises a vehicle which is pharmaceutically acceptable for an injectable formulation.
26. Composition according to one of Claims 11 to 24, characterized in that it t' 10 also comprises a vehicle which is pharmaceutically acceptable for administration Son the skin and/or mucous membranes.
27. Use of a transfecting compound according to one of Claims 1 to 10, for transferring nucleic acids.
28. Use of a transfecting compound according to one of Claims 1 to 10, for manufacturing a medicinal product intended to treat diseases.
29. Method for transferring nucleic acids into cells, characterized in that it comprises the following steps: bringing the nucleic acid into contact with a transfecting compound as defined in any one of Claims 1 to 10, so as to form a complex, and bringing the cells into contact with the complex formed in
30. Method for transferring nucleic acids into cells according to Claim 29, characterized in that said transfer agent and/or said nucleic acid are mixed beforehand with one or more adjuvant(s) and/or with a targeting element as defined in any one of Claims 16 to 23.
31. Method for transferring nucleic acids into cells according to Claim 29, characterized in that one or more adjuvants as defined in any one of Claims 16 to are administered to the cells beforehand.
32. Method for transferring nucleic acids into'cells according to one of Claims 29 to 31, characterized in that the cells are also subjected to chemical or physical treatment. 00
33. Method for treating the human or animal body, comprising the following c steps: t (1)bringing the nucleic acid into contact with a transfecting compound as defined in any one of Claims 1 to 10, so as to form a complex, and N 5 bringing the cells of the human or animal body into contact with the complex formed in
34. Method for treating the human or animal body according to Claim 33, characterized in that said transfer agent and/or said nucleic acid are mixed Cr 10 beforehand with one or more adjuvant(s) and/or with a targeting element as Sdefined in any one of Claims 16 to 23. (N Method for treating the human or animal body according to Claim 34, characterized in that one or more adjuvants as defined in any one of Claims 16 to 20 are administered to said human or animal body beforehand.
36. Method for treating the human or animal body according to one of Claims 33 to 35, characterized in that said human or animal body is also subjected to chemical or physical treatment.
37. Transfection kit, characterized in that it comprises one or more transfecting compounds according to one of Claims 1 to 10 and mixtures thereof.
38. A transfecting compound substantially as hereinbefore described with reference to Examples 1 to 3. Aventis Pharma SA, Centre National de la Recherche Scientifique and Institute National de la Sante et de la Recherche Medicale WATERMARK PATENT TRADE MARK ATTORNEYS P23610AU00
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR01/11199 | 2001-08-29 | ||
FR0111199A FR2829136B1 (en) | 2001-08-29 | 2001-08-29 | LIPID DERIVATIVES OF AMINOGLYCOSIDES |
US33145201P | 2001-11-16 | 2001-11-16 | |
US60/331,452 | 2001-11-16 | ||
PCT/FR2002/002959 WO2003018603A1 (en) | 2001-08-29 | 2002-08-29 | Aminoglycoside lipid derivatives for transfection |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2002334051A1 AU2002334051A1 (en) | 2003-06-05 |
AU2002334051B2 true AU2002334051B2 (en) | 2008-05-15 |
Family
ID=26213158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002334051A Expired AU2002334051B2 (en) | 2001-08-29 | 2002-08-29 | Aminoglycoside lipid derivatives for transfection |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1430074B1 (en) |
JP (1) | JP4629333B2 (en) |
AT (1) | ATE430758T1 (en) |
AU (1) | AU2002334051B2 (en) |
CA (1) | CA2458626C (en) |
DE (1) | DE60232258D1 (en) |
WO (1) | WO2003018603A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2069500B1 (en) * | 2006-10-04 | 2014-09-24 | Centre National De La Recherche Scientifique (Cnrs) | Compositions comprising a sirna and lipidic 4,5-disubstituted 2-deoxystreptamine ring aminoglycoside derivatives and uses thereof |
US8790664B2 (en) | 2008-09-05 | 2014-07-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Multimodular assembly useful for intracellular delivery |
ES2759243T3 (en) | 2014-04-01 | 2020-05-08 | Inst Nat Sante Rech Med | Protected and unprotected RNA molecules and block copolymers for intracellular administration of RNA |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000040692A2 (en) * | 1999-01-05 | 2000-07-13 | Valentis, Inc. | Methods and compositions for delivering nucleic acids |
US6171612B1 (en) * | 1995-11-14 | 2001-01-09 | Aventis Pharma S.A. | Lipopolyamines as transfection agents and pharmaceutical uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4923696A (en) * | 1995-02-10 | 1996-08-27 | Nexstar Pharmaceuticals, Inc. | Lipid constructs for cytoplasmic delivery of agents |
FR2764304B1 (en) * | 1997-06-06 | 1999-07-16 | Rhone Poulenc Rorer Sa | NEW CLASS OF CATIONIC NUCLEIC ACID TRANSFECTANTS |
WO1999012945A2 (en) * | 1997-09-08 | 1999-03-18 | Valentis,Inc. | Hydrophobic glycosylamine derivatives, compositions, and methods for use |
GB9930533D0 (en) * | 1999-12-23 | 2000-02-16 | Mitsubishi Tokyo Pharm Inc | Nucleic acid delivery |
-
2002
- 2002-08-29 EP EP02796324A patent/EP1430074B1/en not_active Expired - Lifetime
- 2002-08-29 DE DE60232258T patent/DE60232258D1/en not_active Expired - Lifetime
- 2002-08-29 AU AU2002334051A patent/AU2002334051B2/en not_active Expired
- 2002-08-29 JP JP2003523262A patent/JP4629333B2/en not_active Expired - Lifetime
- 2002-08-29 CA CA2458626A patent/CA2458626C/en not_active Expired - Lifetime
- 2002-08-29 AT AT02796324T patent/ATE430758T1/en not_active IP Right Cessation
- 2002-08-29 WO PCT/FR2002/002959 patent/WO2003018603A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6171612B1 (en) * | 1995-11-14 | 2001-01-09 | Aventis Pharma S.A. | Lipopolyamines as transfection agents and pharmaceutical uses thereof |
WO2000040692A2 (en) * | 1999-01-05 | 2000-07-13 | Valentis, Inc. | Methods and compositions for delivering nucleic acids |
Also Published As
Publication number | Publication date |
---|---|
JP2005504061A (en) | 2005-02-10 |
JP4629333B2 (en) | 2011-02-09 |
CA2458626C (en) | 2011-05-03 |
EP1430074B1 (en) | 2009-05-06 |
WO2003018603A1 (en) | 2003-03-06 |
DE60232258D1 (en) | 2009-06-18 |
EP1430074A1 (en) | 2004-06-23 |
ATE430758T1 (en) | 2009-05-15 |
CA2458626A1 (en) | 2003-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4467084B2 (en) | Compounds for introducing nucleic acids into cells, their production and their use | |
JP4176831B2 (en) | Lipopolyamine and its pharmaceutical use as transfection agent | |
CZ289513B6 (en) | Lipopolyamine, pharmaceutical composition in which the lipopolyamine is comprised as well as use thereof | |
US6291423B1 (en) | Lipid complexes for transferring at least a therapeutically active substance, in particular a polynucleotide into a target cell and use in gene therapy | |
AU723998B2 (en) | Compounds related to the amidinium family, pharmaceutical compositions containing same, and uses thereof | |
AU737579B2 (en) | New class of cationic transfecting agents for nucleic acids | |
US20050222434A1 (en) | Acid-sensitive compounds, their preparation and uses | |
US7772003B2 (en) | Lipid derivatives of aminoglycosides | |
AU2002334051B2 (en) | Aminoglycoside lipid derivatives for transfection | |
AU4384300A (en) | Transfecting compounds which are sensitive to reducing conditions, pharmaceutical compositions containing them and their applications | |
US6812218B2 (en) | Lipid derivatives of polythiourea | |
CA2421179A1 (en) | Acid-sensitive compounds, preparation and uses thereof | |
AU772033B2 (en) | Novel nucleic acid transferring agents, compositions containing them and uses | |
AU759301B2 (en) | New agents for transferring nucleic acids, compositions containing them and their uses | |
AU2002257904B2 (en) | Polythiourea lipid derivatives | |
CZ430399A3 (en) | Novel class of cationic agents for transferring nucleic acids and pharmaceutical preparations containing thereof | |
MXPA99010765A (en) | Novel class of nucleic acid cationic transfecting agents | |
CZ418599A3 (en) | Compounds, process of their preparation and their application for transferring nucleic acids into cells | |
MXPA99010489A (en) | Compounds, preparation and use for transferring nucleic acids into cells | |
MXPA01005457A (en) | Novel nucleic acid transferring agents, compositions containing them and uses | |
MXPA00008970A (en) | Novel nucleic acid transfer agents, compositions containing same and uses | |
MXPA98006892A (en) | Compounds related to the amidinium family, pharmaceutical compositions containing them and their applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |